Marcy Behar Bolster, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rheumatology | 22 | 2023 | 575 | 6.340 |
Why?
|
| Bone Density Conservation Agents | 8 | 2023 | 771 | 2.070 |
Why?
|
| Osteoporosis | 8 | 2023 | 1576 | 2.030 |
Why?
|
| Scleroderma, Systemic | 22 | 2018 | 312 | 1.850 |
Why?
|
| Arthritis, Rheumatoid | 21 | 2023 | 3688 | 1.570 |
Why?
|
| Education, Medical, Graduate | 9 | 2023 | 2275 | 1.300 |
Why?
|
| Fellowships and Scholarships | 9 | 2023 | 1058 | 1.260 |
Why?
|
| Diphosphonates | 4 | 2023 | 624 | 1.070 |
Why?
|
| Osteoporotic Fractures | 2 | 2022 | 400 | 0.970 |
Why?
|
| Antirheumatic Agents | 10 | 2023 | 1328 | 0.860 |
Why?
|
| Fractures, Bone | 2 | 2023 | 1939 | 0.800 |
Why?
|
| Curriculum | 13 | 2023 | 3575 | 0.750 |
Why?
|
| Muscle Weakness | 1 | 2023 | 412 | 0.720 |
Why?
|
| Education, Distance | 1 | 2023 | 250 | 0.700 |
Why?
|
| Clinical Competence | 8 | 2023 | 4671 | 0.690 |
Why?
|
| Telemedicine | 4 | 2023 | 2844 | 0.650 |
Why?
|
| Hypertension, Pulmonary | 10 | 2018 | 1525 | 0.620 |
Why?
|
| Rheumatic Diseases | 3 | 2023 | 590 | 0.620 |
Why?
|
| Fractures, Stress | 2 | 2015 | 186 | 0.540 |
Why?
|
| Pain Threshold | 6 | 2023 | 583 | 0.530 |
Why?
|
| Health Services Needs and Demand | 2 | 2020 | 1409 | 0.500 |
Why?
|
| Internal Medicine | 2 | 2022 | 996 | 0.490 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2015 | 115 | 0.480 |
Why?
|
| Fibromyalgia | 3 | 2022 | 388 | 0.470 |
Why?
|
| Glucocorticoids | 4 | 2022 | 2100 | 0.460 |
Why?
|
| Orthopedics | 1 | 2022 | 900 | 0.460 |
Why?
|
| Fasciitis | 2 | 2009 | 65 | 0.450 |
Why?
|
| Education, Medical, Continuing | 1 | 2019 | 839 | 0.450 |
Why?
|
| Aromatase Inhibitors | 1 | 2016 | 490 | 0.420 |
Why?
|
| Internship and Residency | 4 | 2022 | 5761 | 0.400 |
Why?
|
| Faculty, Medical | 2 | 2020 | 1179 | 0.390 |
Why?
|
| Proton Pump Inhibitors | 1 | 2016 | 519 | 0.390 |
Why?
|
| Inpatients | 4 | 2023 | 2478 | 0.360 |
Why?
|
| Preventive Health Services | 1 | 2014 | 576 | 0.350 |
Why?
|
| Eosinophilia | 2 | 2009 | 531 | 0.350 |
Why?
|
| Tibia | 1 | 2015 | 1072 | 0.340 |
Why?
|
| Interprofessional Relations | 1 | 2015 | 1008 | 0.330 |
Why?
|
| Vertebroplasty | 1 | 2010 | 77 | 0.330 |
Why?
|
| Pandemics | 4 | 2023 | 8274 | 0.320 |
Why?
|
| Physician Assistants | 3 | 2019 | 194 | 0.320 |
Why?
|
| Humans | 89 | 2023 | 739219 | 0.320 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2016 | 1833 | 0.320 |
Why?
|
| Checklist | 1 | 2015 | 817 | 0.320 |
Why?
|
| Nurse Practitioners | 3 | 2019 | 270 | 0.310 |
Why?
|
| Teaching | 1 | 2015 | 1166 | 0.300 |
Why?
|
| Lung Diseases | 4 | 2021 | 1878 | 0.300 |
Why?
|
| Arthralgia | 3 | 2022 | 457 | 0.290 |
Why?
|
| Raynaud Disease | 3 | 2014 | 65 | 0.290 |
Why?
|
| Bone Density | 2 | 2017 | 3470 | 0.280 |
Why?
|
| Needs Assessment | 3 | 2023 | 1145 | 0.280 |
Why?
|
| Anticonvulsants | 1 | 2016 | 1907 | 0.280 |
Why?
|
| Consensus | 1 | 2015 | 2912 | 0.270 |
Why?
|
| Rheumatoid Factor | 2 | 2020 | 188 | 0.270 |
Why?
|
| Autoimmune Diseases | 2 | 2016 | 2116 | 0.270 |
Why?
|
| Pulmonary Fibrosis | 6 | 2012 | 525 | 0.270 |
Why?
|
| Lung Diseases, Interstitial | 4 | 2014 | 804 | 0.250 |
Why?
|
| Referral and Consultation | 1 | 2016 | 3514 | 0.220 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 2521 | 0.220 |
Why?
|
| Pain Measurement | 8 | 2023 | 3419 | 0.210 |
Why?
|
| Myocardial Infarction | 2 | 2022 | 11666 | 0.210 |
Why?
|
| Cyclophosphamide | 5 | 2007 | 2238 | 0.210 |
Why?
|
| Bronchoalveolar Lavage Fluid | 3 | 2007 | 764 | 0.210 |
Why?
|
| Pain | 7 | 2023 | 4923 | 0.210 |
Why?
|
| Eosinophilia-Myalgia Syndrome | 3 | 1996 | 8 | 0.200 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2003 | 285 | 0.200 |
Why?
|
| Joints | 2 | 2007 | 325 | 0.200 |
Why?
|
| Hemosiderosis | 1 | 2021 | 71 | 0.190 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2021 | 66 | 0.190 |
Why?
|
| Accreditation | 2 | 2022 | 448 | 0.190 |
Why?
|
| Lovastatin | 1 | 2020 | 120 | 0.180 |
Why?
|
| Chronic Periodontitis | 1 | 2021 | 101 | 0.180 |
Why?
|
| Optics and Photonics | 1 | 2002 | 321 | 0.180 |
Why?
|
| Prednisone | 2 | 2022 | 1560 | 0.180 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 9259 | 0.180 |
Why?
|
| Tramadol | 1 | 2020 | 50 | 0.180 |
Why?
|
| Proteinuria | 1 | 2003 | 654 | 0.180 |
Why?
|
| Tomography | 1 | 2002 | 386 | 0.180 |
Why?
|
| Acetaminophen | 1 | 2023 | 541 | 0.170 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2020 | 220 | 0.170 |
Why?
|
| Personnel Selection | 1 | 2021 | 189 | 0.170 |
Why?
|
| Autoantibodies | 2 | 2023 | 2020 | 0.160 |
Why?
|
| Career Mobility | 1 | 2020 | 262 | 0.160 |
Why?
|
| Feedback | 1 | 2022 | 788 | 0.160 |
Why?
|
| Creatinine | 1 | 2023 | 1903 | 0.160 |
Why?
|
| Musculoskeletal System | 1 | 2020 | 175 | 0.160 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 3606 | 0.150 |
Why?
|
| Imidazoles | 1 | 2023 | 1207 | 0.150 |
Why?
|
| Scleroderma, Diffuse | 2 | 2014 | 16 | 0.150 |
Why?
|
| Calcium | 2 | 2023 | 5739 | 0.150 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2002 | 722 | 0.140 |
Why?
|
| Pain Perception | 1 | 2018 | 190 | 0.140 |
Why?
|
| Program Evaluation | 2 | 2016 | 2484 | 0.140 |
Why?
|
| Secondary Prevention | 1 | 2022 | 1516 | 0.140 |
Why?
|
| Catastrophization | 1 | 2019 | 315 | 0.140 |
Why?
|
| Polymyalgia Rheumatica | 1 | 2016 | 54 | 0.130 |
Why?
|
| Decision Making | 1 | 2010 | 3854 | 0.130 |
Why?
|
| Systemic Vasculitis | 1 | 2016 | 37 | 0.130 |
Why?
|
| Adult | 25 | 2023 | 213375 | 0.130 |
Why?
|
| Scleroderma, Limited | 1 | 2014 | 8 | 0.130 |
Why?
|
| Teriparatide | 1 | 2017 | 225 | 0.130 |
Why?
|
| Methotrexate | 1 | 2022 | 1710 | 0.130 |
Why?
|
| Brassica | 1 | 1994 | 38 | 0.130 |
Why?
|
| Sarcoidosis | 2 | 2016 | 507 | 0.130 |
Why?
|
| Physicians, Women | 1 | 2020 | 483 | 0.120 |
Why?
|
| Self-Assessment | 1 | 2016 | 390 | 0.120 |
Why?
|
| Plant Oils | 1 | 1994 | 202 | 0.120 |
Why?
|
| Registries | 4 | 2018 | 8039 | 0.120 |
Why?
|
| Severity of Illness Index | 10 | 2023 | 15510 | 0.110 |
Why?
|
| Gout | 1 | 2020 | 547 | 0.110 |
Why?
|
| Female | 42 | 2023 | 378808 | 0.110 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2017 | 417 | 0.110 |
Why?
|
| Middle Aged | 32 | 2021 | 212833 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 9812 | 0.110 |
Why?
|
| Myositis | 1 | 2016 | 248 | 0.110 |
Why?
|
| Neoplasms, Connective Tissue | 1 | 2013 | 40 | 0.110 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2020 | 1822 | 0.110 |
Why?
|
| Sex Characteristics | 1 | 2023 | 2582 | 0.110 |
Why?
|
| Expert Testimony | 1 | 2015 | 355 | 0.110 |
Why?
|
| Goals | 2 | 2020 | 702 | 0.110 |
Why?
|
| Calcinosis | 1 | 2021 | 1492 | 0.110 |
Why?
|
| Learning | 1 | 2022 | 1693 | 0.110 |
Why?
|
| C-Reactive Protein | 2 | 2022 | 3752 | 0.110 |
Why?
|
| Certification | 1 | 2015 | 423 | 0.100 |
Why?
|
| Giant Cell Arteritis | 1 | 2016 | 291 | 0.100 |
Why?
|
| Scleroderma, Localized | 2 | 2009 | 78 | 0.100 |
Why?
|
| Male | 38 | 2023 | 348967 | 0.100 |
Why?
|
| Myocardial Ischemia | 1 | 2022 | 2145 | 0.100 |
Why?
|
| Biopsy, Needle | 2 | 2009 | 1637 | 0.100 |
Why?
|
| Immunosuppressive Agents | 4 | 2007 | 4143 | 0.100 |
Why?
|
| Bone and Bones | 1 | 2002 | 2574 | 0.100 |
Why?
|
| Risk Factors | 8 | 2022 | 71972 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 1 | 2003 | 2546 | 0.090 |
Why?
|
| Vital Capacity | 4 | 2018 | 922 | 0.090 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2018 | 941 | 0.090 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2020 | 1620 | 0.090 |
Why?
|
| Antigens, CD | 1 | 2020 | 4024 | 0.090 |
Why?
|
| Alcohol Drinking | 1 | 2022 | 3945 | 0.080 |
Why?
|
| Follow-Up Studies | 6 | 2022 | 38941 | 0.080 |
Why?
|
| Femoral Fractures | 1 | 2013 | 376 | 0.080 |
Why?
|
| United States | 7 | 2022 | 69568 | 0.080 |
Why?
|
| Pregnancy Complications | 1 | 2003 | 2867 | 0.080 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2016 | 1557 | 0.080 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 4662 | 0.080 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2002 | 4025 | 0.080 |
Why?
|
| Fractures, Compression | 1 | 2010 | 133 | 0.080 |
Why?
|
| Aged | 19 | 2021 | 162667 | 0.080 |
Why?
|
| Selection Bias | 1 | 2010 | 370 | 0.080 |
Why?
|
| History, 20th Century | 1 | 2016 | 2741 | 0.080 |
Why?
|
| Drug Discovery | 1 | 2016 | 1056 | 0.080 |
Why?
|
| Vitamins | 1 | 2016 | 1602 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 4377 | 0.070 |
Why?
|
| Ultrasonography | 1 | 2020 | 5941 | 0.070 |
Why?
|
| Treatment Outcome | 11 | 2023 | 62691 | 0.070 |
Why?
|
| Critical Pathways | 1 | 2010 | 475 | 0.070 |
Why?
|
| Cohort Studies | 4 | 2022 | 40385 | 0.070 |
Why?
|
| Data Collection | 1 | 2015 | 3340 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 3233 | 0.060 |
Why?
|
| Societies, Medical | 1 | 2017 | 3738 | 0.060 |
Why?
|
| Tryptophan | 2 | 1996 | 477 | 0.060 |
Why?
|
| Apoptosis | 1 | 2020 | 9708 | 0.060 |
Why?
|
| Leukocyte Count | 1 | 2007 | 1583 | 0.060 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2016 | 2091 | 0.060 |
Why?
|
| Dietary Supplements | 1 | 2016 | 3279 | 0.060 |
Why?
|
| Pulmonary Artery | 1 | 2012 | 1909 | 0.060 |
Why?
|
| Double-Blind Method | 5 | 2020 | 11985 | 0.060 |
Why?
|
| Spinal Fractures | 1 | 2010 | 697 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2003 | 6478 | 0.050 |
Why?
|
| Anesthetics, Local | 1 | 2010 | 985 | 0.050 |
Why?
|
| Eosinophils | 1 | 2007 | 954 | 0.050 |
Why?
|
| Pregnancy, High-Risk | 1 | 2003 | 120 | 0.050 |
Why?
|
| Hypertension, Renal | 1 | 2003 | 177 | 0.050 |
Why?
|
| Vitamin D | 1 | 2016 | 3197 | 0.050 |
Why?
|
| Hemodynamics | 3 | 2016 | 4196 | 0.050 |
Why?
|
| Ulnar Artery | 1 | 2002 | 17 | 0.050 |
Why?
|
| Cytokines | 1 | 1997 | 7296 | 0.050 |
Why?
|
| Absorption | 1 | 2002 | 249 | 0.050 |
Why?
|
| Antihypertensive Agents | 2 | 2003 | 2039 | 0.050 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2007 | 851 | 0.050 |
Why?
|
| Disease Progression | 3 | 2020 | 13237 | 0.050 |
Why?
|
| Gingival Crevicular Fluid | 1 | 2021 | 90 | 0.050 |
Why?
|
| Cross-Sectional Studies | 5 | 2023 | 24711 | 0.050 |
Why?
|
| Peptides, Cyclic | 1 | 2023 | 401 | 0.050 |
Why?
|
| Fetal Death | 1 | 2003 | 446 | 0.050 |
Why?
|
| Intubation | 1 | 2020 | 141 | 0.050 |
Why?
|
| South Carolina | 2 | 2013 | 99 | 0.050 |
Why?
|
| Respiratory Function Tests | 3 | 2012 | 1611 | 0.050 |
Why?
|
| Respiratory Therapy | 1 | 2020 | 133 | 0.040 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2003 | 732 | 0.040 |
Why?
|
| Epoprostenol | 1 | 2000 | 252 | 0.040 |
Why?
|
| Chickens | 1 | 2002 | 864 | 0.040 |
Why?
|
| Prospective Studies | 7 | 2019 | 53036 | 0.040 |
Why?
|
| Hospitalization | 1 | 2018 | 10208 | 0.040 |
Why?
|
| Videoconferencing | 1 | 2021 | 194 | 0.040 |
Why?
|
| Gout Suppressants | 1 | 2020 | 158 | 0.040 |
Why?
|
| Electronics | 1 | 2020 | 322 | 0.040 |
Why?
|
| Carpal Tunnel Syndrome | 1 | 2001 | 296 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2021 | 1585 | 0.040 |
Why?
|
| Lung | 2 | 2014 | 9778 | 0.040 |
Why?
|
| Chemokine CCL3 | 1 | 1997 | 83 | 0.040 |
Why?
|
| Chemokine CCL4 | 1 | 1997 | 128 | 0.040 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2002 | 792 | 0.040 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 1997 | 122 | 0.040 |
Why?
|
| Metacarpophalangeal Joint | 1 | 2017 | 82 | 0.040 |
Why?
|
| Radiography, Thoracic | 1 | 2003 | 1262 | 0.040 |
Why?
|
| Saliva | 1 | 2021 | 805 | 0.040 |
Why?
|
| Ulna | 1 | 2017 | 133 | 0.040 |
Why?
|
| Fingers | 2 | 2002 | 511 | 0.040 |
Why?
|
| Chemokine CCL5 | 1 | 1997 | 209 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 15069 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2005 | 1162 | 0.030 |
Why?
|
| Longitudinal Studies | 4 | 2014 | 13880 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2012 | 8553 | 0.030 |
Why?
|
| Sex Factors | 2 | 2020 | 10397 | 0.030 |
Why?
|
| CREST Syndrome | 1 | 1995 | 6 | 0.030 |
Why?
|
| Neutrophils | 1 | 2007 | 3698 | 0.030 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2014 | 88 | 0.030 |
Why?
|
| Workplace | 1 | 2021 | 837 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2020 | 2614 | 0.030 |
Why?
|
| Total Lung Capacity | 2 | 2007 | 143 | 0.030 |
Why?
|
| Radius | 1 | 2017 | 422 | 0.030 |
Why?
|
| Uric Acid | 1 | 2020 | 753 | 0.030 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2018 | 502 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2021 | 2533 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2003 | 12945 | 0.030 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 1994 | 194 | 0.030 |
Why?
|
| Pre-Eclampsia | 1 | 2003 | 1194 | 0.030 |
Why?
|
| Hospitals, University | 2 | 2006 | 567 | 0.030 |
Why?
|
| Fibrosis | 1 | 2020 | 2024 | 0.030 |
Why?
|
| Osteomalacia | 1 | 2013 | 53 | 0.030 |
Why?
|
| North Carolina | 1 | 2013 | 310 | 0.030 |
Why?
|
| Connective Tissue Diseases | 1 | 1995 | 264 | 0.030 |
Why?
|
| Inflammation | 2 | 2022 | 10531 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2020 | 12235 | 0.030 |
Why?
|
| Bone Nails | 1 | 2013 | 218 | 0.020 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2013 | 151 | 0.020 |
Why?
|
| Leadership | 1 | 2020 | 1349 | 0.020 |
Why?
|
| Peptides | 1 | 2023 | 4392 | 0.020 |
Why?
|
| Fracture Fixation, Intramedullary | 1 | 2013 | 156 | 0.020 |
Why?
|
| Animals | 4 | 2017 | 168358 | 0.020 |
Why?
|
| Age Factors | 1 | 2007 | 18347 | 0.020 |
Why?
|
| Quality of Life | 3 | 2007 | 12640 | 0.020 |
Why?
|
| Linear Models | 1 | 2020 | 5946 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1997 | 3863 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 11348 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2002 | 3605 | 0.020 |
Why?
|
| Skin | 1 | 2003 | 4324 | 0.020 |
Why?
|
| Young Adult | 2 | 2020 | 56252 | 0.020 |
Why?
|
| Administration, Oral | 2 | 2007 | 3909 | 0.020 |
Why?
|
| Incidence | 1 | 2007 | 20912 | 0.020 |
Why?
|
| Forecasting | 1 | 2018 | 2952 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2015 | 1205 | 0.020 |
Why?
|
| Syndrome | 1 | 1994 | 3241 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2020 | 9846 | 0.020 |
Why?
|
| Collagen | 1 | 1996 | 2669 | 0.020 |
Why?
|
| Boston | 1 | 2020 | 9314 | 0.020 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2007 | 120 | 0.020 |
Why?
|
| Exercise Test | 1 | 2014 | 2069 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2020 | 8272 | 0.020 |
Why?
|
| Program Development | 1 | 2013 | 1313 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2017 | 20038 | 0.020 |
Why?
|
| Motor Activity | 1 | 1996 | 2718 | 0.020 |
Why?
|
| Tomography, Spiral Computed | 1 | 2007 | 279 | 0.020 |
Why?
|
| Leukopenia | 1 | 2006 | 207 | 0.020 |
Why?
|
| Echocardiography | 1 | 2018 | 5098 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 4400 | 0.020 |
Why?
|
| Logistic Models | 1 | 2020 | 13400 | 0.020 |
Why?
|
| Depression | 1 | 2005 | 7689 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2002 | 8919 | 0.020 |
Why?
|
| Survival Rate | 1 | 2018 | 12760 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2016 | 5073 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 12328 | 0.010 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 3649 | 0.010 |
Why?
|
| Forced Expiratory Volume | 1 | 2007 | 1740 | 0.010 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 19787 | 0.010 |
Why?
|
| Cognition Disorders | 1 | 1996 | 4026 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2003 | 23292 | 0.010 |
Why?
|
| Time Factors | 2 | 2018 | 40040 | 0.010 |
Why?
|
| Health Status Indicators | 1 | 2007 | 969 | 0.010 |
Why?
|
| Sympathectomy | 1 | 2002 | 89 | 0.010 |
Why?
|
| Risk | 1 | 2014 | 9684 | 0.010 |
Why?
|
| Median Nerve | 1 | 2001 | 130 | 0.010 |
Why?
|
| Hypesthesia | 1 | 2001 | 110 | 0.010 |
Why?
|
| Pregnancy | 1 | 2003 | 29003 | 0.010 |
Why?
|
| Paresthesia | 1 | 2001 | 159 | 0.010 |
Why?
|
| Ulcer | 1 | 2002 | 205 | 0.010 |
Why?
|
| Antibodies, Antinuclear | 1 | 2002 | 325 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 57639 | 0.010 |
Why?
|
| Disability Evaluation | 1 | 2007 | 1824 | 0.010 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2000 | 264 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 4935 | 0.010 |
Why?
|
| Age of Onset | 1 | 2006 | 3263 | 0.010 |
Why?
|
| Cognition | 1 | 1996 | 6686 | 0.010 |
Why?
|
| Saphenous Vein | 1 | 2002 | 527 | 0.010 |
Why?
|
| Cardiac Output | 1 | 2000 | 857 | 0.010 |
Why?
|
| Quality Improvement | 1 | 2013 | 3730 | 0.010 |
Why?
|
| Echocardiography, Doppler | 1 | 2000 | 934 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2006 | 6451 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2000 | 2270 | 0.010 |
Why?
|
| Swimming | 1 | 1996 | 205 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2020 | 76632 | 0.010 |
Why?
|
| Maze Learning | 1 | 1996 | 477 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1996 | 1583 | 0.010 |
Why?
|
| Vascular Surgical Procedures | 1 | 2002 | 1471 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1996 | 1938 | 0.010 |
Why?
|
| Health Status | 1 | 2005 | 4013 | 0.010 |
Why?
|
| Reaction Time | 1 | 1996 | 2097 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 1996 | 21859 | 0.000 |
Why?
|
| Analysis of Variance | 1 | 1996 | 6364 | 0.000 |
Why?
|
| Disease Models, Animal | 2 | 1996 | 18002 | 0.000 |
Why?
|
| Anticoagulants | 1 | 2002 | 4582 | 0.000 |
Why?
|
| Kidney Diseases | 1 | 1997 | 2140 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 35274 | 0.000 |
Why?
|
| Body Weight | 1 | 1996 | 4659 | 0.000 |
Why?
|
| RNA, Messenger | 1 | 1996 | 13006 | 0.000 |
Why?
|
| Mice | 2 | 1996 | 80995 | 0.000 |
Why?
|
| Prognosis | 1 | 1997 | 28901 | 0.000 |
Why?
|